| Document |
Document Title |
|
WO/2021/096886A1 |
Various aspects of this patent document relate to compositions and methods to purify cannabinoids by crystallization in a water-miscible liquid.
|
|
WO/2021/093009A1 |
A pure-color membrane (20) and a preparation method therefor and a display device. The pure-color membrane (20) comprises a transparent substrate and a pure-color substance dispersed in the transparent substrate; the pure-color substance...
|
|
WO/2021/096882A1 |
Compositions, methods, and kits useful for treating obesity conditions are provided herein. Such compositions can contain synergizing amounts of nicotinamide riboside and/or nicotinamide mononucleotide and/or nicotinic acid metabolites i...
|
|
WO/2021/085372A1 |
An embodiment of the present invention pertains to a resin composition, a compound (Z), an optical filter, or a solid-state imaging device and optical sensor device using the optical filter. The resin composition contains a resin, and a ...
|
|
WO/2021/087127A1 |
The invention relates to cannabinoid compounds, pharmaceutical compositions including one or more cannabinoid compounds, and the use of pharmaceutical compositions including one or more cannabinoid compounds for the treatment of a diseas...
|
|
WO/2021/081634A1 |
A combination that includes: a flavonoid, for example in an amount from about 0.1 g to about 1.5 g; and one or more of: ascorbic acid, ascorbate, or a combination thereof, for example in an amount from about 0.2 g to about 2.0 g; N-acety...
|
|
WO/2021/086675A2 |
A solvent-free method for converting CBD or delta-9 THC-A to delta-9 THC and delta-8 THC includes adding CBD to a reaction vessel, streaming an inert gas through the reaction vessel, heating the CBD while stirring to melt the CBD, stirri...
|
|
WO/2021/081640A1 |
Disclosed herein is a high-effective-concentration cannabinoid-based vape oil that is flowable within a vape device. The high-effective-concentration cannabinoid-based vape oil comprises a cannabinoid-based incipient and a cannabinoid-ba...
|
|
WO/2021/077926A1 |
Disclosed is an industrializable method for leaching xanthophyll and quercetagetin from particles of marigold flowers. The method comprises the following steps: 1) leaching particles of marigold flowers with a solution of acetone having ...
|
|
WO/2021/078811A1 |
The present invention concerns compounds of Formula (1), pharmaceutically acceptable salts, solvates or prodrugs thereof, pharmaceutical compositions comprising the same, and the use of the same in treating or preventing a disease.
|
|
WO/2021/072555A1 |
A composition comprising curcumin, resveratrol, quercetin and inositol hexaphosphate. The composition has potential utility in treating high blood sugar, diabetes, heart disease and other chronic conditions including fibromyalgia and col...
|
|
WO/2021/076938A1 |
Disclosed are a series of compounds or their tautomers having a general structure represented by Formula (la), (lb), (Ila), (lIb), or (lIc) and pharmaceutically acceptable salts thereof. The present disclosure also relates to pharmaceuti...
|
|
WO/2021/075456A1 |
A photochromic compound according to the present invention is characterized by comprising at least two monovalent photochromic basic structural groups PC that include a T-type photochromic site, wherein the photochromic base structural g...
|
|
WO/2021/076633A1 |
The present disclosure relates to polymorphs of D9-THC-naphthoylester for the preparation of D9-Tetrahydrocannabinol in high yields and high purity, methods of preparing the D9-Tetrahydrocannabinol, and compositions comprising the D9-Tet...
|
|
WO/2021/070152A1 |
The present invention relates to novel coumarin glyoxylates, a process for their preparation and their use as photoinitiators in photopolymerization compositions. The invention also concerns a process for the photopolymerization of compo...
|
|
WO/2021/068501A1 |
Provided is a method for synthesizing myricetin, the method comprising the following steps: adding an alkaline solution to an aqueous solution of dihydromyricetin, and after the addition is completed, heating under a reflux state; adding...
|
|
WO/2021/068952A1 |
A structurally novel benzodihydropyran compound targeting AKR1C3 enzyme (aldo-keto reductase 1C3). In particular, disclosed is a compound represented by formula (II) or a pharmaceutically acceptable salt or isomer thereof.
|
|
WO/2021/064189A2 |
The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them hig...
|
|
WO/2021/066435A1 |
The present invention relates to a compound for an organic electric element, an organic electric element using same, and an electronic device comprising the organic electric element. According to the present invention, an organic electri...
|
|
WO/2021/067627A1 |
Methods for converting mixtures of anthocyanins occurring in fruit or vegetable juice or extract into particular anthocyanin molecules having desirable colorant properties are provided herein. The method of the present disclosure can be ...
|
|
WO/2021/062555A1 |
Topical formulations comprising one or more cannabinoids, one or more terpenes, and one or more flavonoids; and methods and uses thereof for the treatment of an integumentary wound, wherein the one or more cannabinoids comprise tetrahydr...
|
|
WO/2021/062561A1 |
There is provided a method for cultivating and harvesting cannabis plants, comprising: cultivating a batch of a plurality of cannabis plants in a grow area, processing plant material from a portion of the plurality of cannabis plants in ...
|
|
WO/2021/062557A1 |
This disclosure relates generally to cannabinoid derivatives having the formula (I), wherein R4 is hydrogen, -C(Q1)N(R4a)(R4b) or -C(R4J)(R4k)N(R4e)C(0)R4f, R6 is hydrogen, -C(Q2)N(R6a)(R6b) or -C(R6J)(R6k)N(R6e)C(0)R6f, provided that R6...
|
|
WO/2021/062482A1 |
The invention relates to compounds that have antiviral activity, particularly 4-oxochromane derivatives that have antiviral activity against viruses of the Family Flaviviridae. Methods of treating viruses with the 4-oxochromane compounds...
|
|
WO/2021/060276A1 |
Provided, inter alia, is a fluorinating agent that can selectively produce a monofluorination product through preferential synthesis of the monofluorination product over a difluorination product, in a fluorination reaction in which a flu...
|
|
WO/2021/060691A1 |
The present invention provides type I crystals, type II crystals, type III crystals, and type IV crystals which are novel crystalline forms of 2-(2,5-difluorophenyl)-3-carboxy-7-chloro-(4H)-4-benzopyrano
ne. In particular, the type IV cr...
|
|
WO/2021/054714A1 |
The present application provides: a heterocyclic compound capable of significantly improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device; and an organic light-emitting de...
|
|
WO/2021/053205A1 |
The present invention relates to chromen-4-one derivatives comprising a quaternary group, and to associated multi-salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds ...
|
|
WO/2021/046630A1 |
A process for producing THC-O-acetate using a succession of distillation, salting-out assisted liquid-liquid extractions (SALLEs), and solvent recovery techniques. Tetrahydrocannabinol (THC) in cannabis oil dissolved in hexane reacts wit...
|
|
WO/2021/046628A1 |
A stable medicinal cannabidiol composition for use in oral delivery, the composition comprising synthetic cannabidiol (CBD) having a purity of at least 99.8 %, preferably at least 99.9 %, together with beta-caryophyllene (BCP) which func...
|
|
WO/2021/046640A1 |
The present disclosure relates to new cannabinoid derivatives and precursors and catalytic asymmetric processes for their preparation. The disclosure also relates to pharmaceutical compositions and pharmaceutical and analytical uses of t...
|
|
WO/2021/046636A1 |
The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.
|
|
WO/2021/050449A1 |
Provided herein are compositions and methods of ameliorating the pharmaceutical aversiveness of active pharmaceutical ingredient (API) by administering the API after or substantially simultaneously with a flavone compound.
|
|
WO/2021/051015A1 |
The inventions relate to the use of anti-hemichannel compounds, including anti-connexin 43 hemichannel opening compounds, to rescue or restore retinal function, to rescue or restore retinal structure, and/or to rescue or restore choroida...
|
|
WO/2021/035342A1 |
Disclosed herein is a method for converting tetrahydrocannabinolic acid (THCA) to cannabinolic acid (CBNA). The method comprises contacting an input material comprising THCA with a benzoquinone reagent under reaction conditions comprisin...
|
|
WO/2021/035344A1 |
Disclosed herein is a method for upgrading a cannabinoid mixture that comprises tetrahydrocannabinol (THC) and one or more non-THC cannabinoids, when the cannabinoid mixture has a THC content of less than about 20 wt. %. The method compr...
|
|
WO/2021/040203A1 |
Salts and a crystal form of a compound in chemical formula 1, namely 2-(2,5-difluorophenyl)-3- carboxy-7-chloro-(4H)-4-benzopyranone, according to the present invention are excellent in terms of various physicochemical properties, namely...
|
|
WO/2021/041637A1 |
Various aspects of this patent document relate to cannabinoid ions that are dissolved in glycerol, in which the cannabinoid ions are not carboxylates.
|
|
WO/2021/035340A1 |
Disclosed herein is a method of converting a THC-rich cannabinoid mixture that comprises at least about 20 % THC into a CBN-rich cannabinoid mixture that comprises at least about 2.0 % CBN. The method comprises contacting the cannabinoid...
|
|
WO/2021/038889A1 |
The present invention provides novel methods for producing a compound represented by formula (I) and either a compound represented by formula (B), which is an intermediate of the compound of formula (I), or a salt thereof.
|
|
WO/2021/041107A1 |
The current invention is in the field of molecular biology/pharmacology and provides novel 3-oxabicyclo [3.3.1] nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ER...
|
|
WO/2021/039023A1 |
The present invention provides, inter alia, a novel method for producing a compound represented by formula (I) and a novel method for producing a compound represented by formula (B) or a salt thereof, which are intermediates in the produ...
|
|
WO/2021/030913A1 |
The present disclosure relates to cannabinoid compositions that are rehydratable and that upon such rehydration retain at least some of the properties of the original cannabinoid emulsions from which the cannabinoid composition was obtai...
|
|
WO/2021/032643A1 |
The present invention relates to a compound of the general formula I and the pharmaceutically acceptable salts thereof; where the variables are as defined in the claims and the description. The invention also relates to the compounds of ...
|
|
WO/2021/034089A1 |
The present invention relates to a compound for an organic electronic element, an organic electronic element using same, and an electronic device including the organic electronic element. According to the present invention, an organic el...
|
|
WO/2021/031622A1 |
Disclosed is a method for extracting and separating dihydromyricetin from Ampelopsis grossedentata tea, belonging to the technical field of natural medicine extraction and separation. The specific steps are as follows: 1) weighing Ampelo...
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/025162A1 |
A compound represented by formula (1) (wherein L1 and L2 are given linking groups and Ar1 is a monovalent group having a structure represented by formula (2)).
|
|
WO/2021/026257A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
|
|
WO/2021/025444A1 |
Despite various functions discovered of polyphenol-based compounds in regulating biological responses, such compounds, due to difficulty in procuring same in sufficient amounts with a high enough purity to permit application in pharmaceu...
|
